Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: XERS

Xeris Biopharma Holdings, Inc.

Healthcare | Biotechnology

No licensed closing price on file for XERS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.10

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:05 UTC.

What Xeris Biopharma Holdings, Inc. does

Xeris Biopharma is a commercial-stage biopharmaceutical company that develops and sells therapies for chronic endocrine and neurological diseases in the United States. The company markets three approved products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia in people with diabetes, and Keveyis for Primary Periodic Paralysis. In its pipeline, Xeris is developing XP-8121, a once-weekly subcutaneous levothyroxine injection for hypothyroidism, leveraging its proprietary non-aqueous formulation technology called XeriSol.

Summarized from Xeris Biopharma Holdings, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.10

Revenue, margins & earnings

FY2021: net loss $123M on revenue $50M$50MFY2021FY2022: net loss $95M on revenue $110M$110MFY2022FY2023: net loss $62M on revenue $164M$164MFY2023FY2024: net loss $55M on revenue $203M$203MFY2024FY2025 Taxes & interest: $24MFY2025 Operating costs: $267M$292MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02See RemarksSale-15,000$141.1K
  • 2026-10-02See RemarksSale-16,666$156.8K
  • 2026-10-02See RemarksSale-5,000$47.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Xeris Biopharma Holdings, Inc. do?

Xeris Biopharma is a commercial-stage biopharmaceutical company that develops and sells therapies for chronic endocrine and neurological diseases in the United States.

When did XERS last file with the SEC?

Xeris Biopharma Holdings, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:05 UTC. This page is also available as JSON at /api/data?ticker=XERS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for XERS and 5,000+ tickers.

Create a free account — keep XERS
For your agent
GET /api/data?ticker=XERS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt